Got questions about in silico drug development?

Will artificial intelligence help optimize biopharma R&D? Proponents say in silico science could cut down the time it takes to generate novel drug candidates — matching targets with molecules via algorithms rather than via wet lab. But is the science, thus far, overblown? What are the challenges — both practical, and ethical? 

STAT reporters Casey Ross and Kate Sheridan will be teasing apart the intricacies of these issues on Wednesday as part of a webinar on the latest applications of AI in the drug development process. 

Register here.